Global Pediatric Congenital Athymia Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2023 |
 Market Size (Base Year) |
USD 1,728.45 Billion |
 Market Size (Forecast Year) |
USD 4,964.24 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球儿童先天性无胸腺治疗市场，按治疗类型（再生先进医学治疗、激素替代疗法）、治疗（药物、手术、腭成形术）、最终用户（医院、家庭护理、专科中心、其他）、分销渠道（医院药房、网上药房、零售药房）划分 - 行业趋势和预测到 2030 年。
儿童先天性无胸腺症治疗市场分析及规模
预测期内，儿童先天性无力症治疗市场预计将出现大幅增长。脆弱的 Di-George 综合征儿童人群、治疗中枢神经系统和心血管疾病等严重疾病的药物的出现以及研发步伐的加快是儿童先天性无力症治疗市场的主要市场驱动因素。
Data Bridge Market Research 分析了 2023-2030 年预测期内儿童先天性无胸腺症治疗市场的增长率。在上述预测期内，儿童先天性无胸腺症治疗市场的预期复合年增长率趋于 4% 左右。2022 年市场价值为 1 亿美元，到 2030 年将增长至 1.3686 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。
儿童先天性无胸腺症治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
治疗类型（再生先进医学治疗、激素替代疗法）、治疗方法（药物、手术、腭成形术）、最终用户（医院、家庭护理、专科中心、其他）、分销渠道（医院药房、网上药房、零售药房） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Sumitomo Pharma Co., Ltd (Japan), CELGENE CORPORATION (U.S.), CELLECTAR BIOSCIENCES, INC (U.S.), eFFECTOR Therapeutics, Inc (U.S.), IMV Inc (Canada), Karyopharm (U.S.), Novartis AG (Switzerland) |
|
Market Opportunities |
|
Market Definition
Pediatric congenital athymia is a rare type of condition that is associated with complete anomaly of Di-George, charging syndrome and deficiency of FOXN1. Children who are suffering from this condition are born without a thymus, leading to extreme immunodeficiency because of the inability to produce normally functioning T cells, that protect against infection and control important immune system processes. Multiple genetic abnormalities, congenital syndromes, and environmental factors that are being associated, and the care of these infants is complex.
Global Pediatric congenital athymia treatment Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Growing awareness among patients and numerous healthcare professionals for treating different types of congenital syndromes and more and more usage of combination therapy are the major factors projected to boost the demand for pediatric congenital athymia market during the forecast period of 2023-2030.
- Increased Clinical Studies and Government Initiatives
The market growth is fuelled by an increase in the number of R&D activities. This will provide beneficial opportunities for the pediatric drugs market growth. The presence of several measures such as the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) is driving big businesses to improve their R&D investments in pediatric drug research. Along with this, increasing drug approvals and launches will further boost the market’s growth rate.
Opportunities
- Increasing Demand for Retail Pharmacies
Increase in the number of pediatric congenital athymia therapeutics being delivered through retail pharmacies and also increase in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition to this, patients opt for retail pharmacies for purchasing drugs, due to its easy accessibility .
- Increasing Incidence of Chronic Disorders
The increasing prevalence of chronic disorders is estimated to enhance the market's growth. Chronic disorders such as asthma, birth defects, anorexia, growth deficiencies, diabetes, juvenile diabetes, cancer in children, and attention deficit hyperactivity among others is the major factor enhancing the demand of pediatric drugs, influencing the market dynamics.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global pediatric congenital athymia treatment market during the forecast period.
- Side Effects
The side effects associated with pediatric congenital athymia drugs, including headache, anxiety, and lack of awareness among people, will act as restrain and further hinder the market's growth rate during the forecast period.
This pediatric congenital athymia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric congenital athymia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- In October 2021, the U.S. FDA announced the approval of rethymic used to treat paediatric patients suffering from congenital athymia. Rethymic is the first thymus tissue product approved in the U.S.
Global Pediatric Congenital Athymia Treatment Scope
The pediatric congenital athymia treatment market is segmented on the basis of therapy type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
- Regenerative Advanced Medicine Therapy
- Hormonal Replacement Therapy
Treatment
- Medication
- Surgery
- Palatoplasty
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Pediatric Congenital Athymia Treatment Market Regional Analysis/Insights
The pediatric congenital athymia treatment market is analyzed and market size insights and trends are provided by therapy type, treatment, distribution channel and end-user as referenced above.
儿童先天性无胸腺治疗市场报告涉及的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于拥有先进的技术、医疗保健支出和技术熟练的专业人员，北美预计将拥有最高的市场增长。
由于对此类罕见疾病缺乏认识，亚太地区占据了市场主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球儿童先天性无胸腺症治疗市场份额分析
儿童先天性无胸腺症治疗市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对儿童先天性无胸腺症治疗市场的关注有关。
儿童先天性无胸腺症治疗市场的主要参与者包括：
- 强生私人有限公司（美国）
- 雅培（美国）
- AbbVie Inc.（美国）
- Bausch Health Companies Inc.（加拿大）
- Biora Therapeutics, Inc（美国）
- 勃林格殷格翰国际有限公司 (德国)
- 安进公司 (美国)
- 辉瑞公司 (美国)
- F. Hoffmann-La Roche Ltd（瑞士）
- Mylan NV（美国）
- 住友制药株式会社（日本）
- CELGENE 公司（美国）
- CELLECTAR BIOSCIENCES, INC（美国）
- eFFECTOR Therapeutics, Inc（美国）
- IMV Inc（加拿大）
- Karyopharm (美国)
- 诺华公司（瑞士）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
